Robert Lorne Hopfner - 11 May 2023 Form 4 Insider Report for Inozyme Pharma, Inc. (INZY)

Role
Director
Signature
/s/ Robert Hopfner
Issuer symbol
INZY
Transactions as of
11 May 2023
Transactions value $
$2,849,998
Form type
4
Filing time
15 May 2023, 17:06:16 UTC
Previous filing
30 Mar 2023
Next filing
19 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INZY Common Stock Purchase $1.42M +219K +6.82% $6.48 3.43M 11 May 2023 By Pivotal F1, F2, F3
transaction INZY Common Stock Purchase $1.43M +229K +6.66% $6.25 3.66M 12 May 2023 By Pivotal F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 2,771,391 of the reported shares are held directly by Pivotal bioVenture Partners Fund I, L.P and 661,425 of the reported shares are held by Pivotal bioVenture Partners Fund II, L.P. (collectively, "Pivotal").
F2 The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner").
F3 Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings LImited ("NFIHL"), which is wholly owned by Nan Fung Group Holdings Limited ("NFGHL"). The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. Such persons and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein.
F4 2,804,062 of the reported shares are held directly by Pivotal bioVenture Partners Fund I, L.P and 857,456 of the reported shares are held by Pivotal bioVenture Partners Fund II, L.P.